Redcare Pharmacy’s Revenue Surge Masks a Deepening Valuation Crisis

Redcare Pharmacy posts €848M Q1 sales (+18% YoY) but shares drop 25% in 2025, as leadership exits and margin pressures cloud profitability outlook.

The numbers are impressive, but the stock tells a different story. Redcare Pharmacy posted first-quarter sales of €848 million, a jump of more than 18% year-on-year, yet its shares have lost over a quarter of their value since January. The disconnect between operational momentum and market sentiment has rarely been wider.

A Boardroom Departure Adds Uncertainty

The company is navigating a leadership transition at a critical juncture. Dirk Brüse, the chief commercial officer, is stepping down after nearly nine years for personal reasons. CEO Olaf Heinrich has taken over his responsibilities on an interim basis. The shake-up comes as Redcare pushes ahead with Germany’s shift to electronic prescriptions, a transformation that demands steady hands.

Insider ownership of nearly 14% offers some reassurance to investors during this period of flux. The management’s skin in the game is seen as a stabilizing force, particularly as the company works to integrate its digital infrastructure with the national telematics system. Redcare recently became the first pharmacy to roll out a fully digital identity solution, replacing physical cards and speeding up e-prescription processing.

The Growth Engine Is Running Hot

Prescription medicines in the DACH region remain the standout performer. Revenue from this segment surged 55% in Germany alone, outpacing the company’s own full-year guidance of low-double-digit percentage growth. Over-the-counter sales also contributed to the top line, reinforcing the breadth of the expansion.

But growth comes at a cost. Redcare is pouring capital into a new logistics hub in Pilsen, Czech Republic, to boost capacity. The investment is squeezing margins hard. Management has already trimmed its medium-term profitability target to above 5%, and for the current year, it expects an operating margin of at least 2.5% — a far cry from the double-digit returns investors once hoped for.

Analysts Are Split on the Stock’s True Worth

The valuation debate is unusually polarized. Barclays recently slashed its price target to €70, with analyst Guillaume Galland cutting revenue forecasts for the coming years. On the other end of the spectrum, Jefferies maintains a target of €150. The chasm between these estimates underscores the market’s deep uncertainty about Redcare’s path to sustainable profits.

Technical indicators paint an even bleaker picture. The relative strength index has fallen to 15.9, a level that signals extreme overselling. The stock traded at around €49.54 on Thursday, recovering slightly from recent lows but still far below its levels from a year ago.

The Profitability Check Is Coming

After posting a loss in the previous fiscal year, analysts expect Redcare to turn profitable within three years. Automation and higher-margin segments like the marketplace model are expected to drive margin expansion. But the immediate focus is on the full quarterly report due May 6, when management will need to provide concrete details on margins, cash flow, and the return on its heavy investments.

Heinrich, who is now temporarily running the commercial division alongside his CEO duties, faces the challenge of convincing investors that the spending spree will soon pay off. The market is not in a forgiving mood.